
ATYR
aTyr Pharma Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.900
Open
5.670
VWAP
5.72
Vol
3.81M
Mkt Cap
518.90M
Low
5.4587
Amount
21.78M
EV/EBITDA(TTM)
--
Total Shares
89.00M
EV
443.66M
EV/OCF(TTM)
--
P/S(TTM)
--
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
Show More
7 Analyst Rating

283.02% Upside
Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 22.33 USD with a low forecast of 16.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy

283.02% Upside
Current: 5.830

Low
16.00
Averages
22.33
High
35.00

283.02% Upside
Current: 5.830

Low
16.00
Averages
22.33
High
35.00
Wells Fargo
Derek Archila
Overweight
maintain
$17 -> $25
2025-06-21
Reason
Wells Fargo
Derek Archila
Price Target
$17 -> $25
2025-06-21
maintain
Overweight
Reason
Wells Fargo analyst Derek Archila raised the firm's price target on aTyr Pharma to $25 from $17 and keeps an Overweight rating on the shares. The firm is increasing its probability of success to 50% that efzo demonstrates statistical significance steroid reduction but also benefits on QOL in the upcoming Phase 3 read out for pulmonary sarcoidosis in early September. Wells would be a buyer ahead of data.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$35
2025-03-14
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$35
2025-03-14
Reiterates
Strong Buy
Reason
Leerink Partners
Faisal Khurshid
Buy
Initiates
$16
2025-02-18
Reason
Leerink Partners
Faisal Khurshid
Price Target
$16
2025-02-18
Initiates
Buy
Reason
Cantor Fitzgerald
Prakhar Agrawal
Buy
Initiates
n/a
2025-01-06
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
n/a
2025-01-06
Initiates
Buy
Reason
Cantor Fitzgerald initiated coverage of aTyr Pharma with an Overweight rating. aTyr Pharma's lead drug Efzofitimod is in two trials for interstitial lung diseases, a Phase 3 trial in pulmonary sarcoidosis, inflammatory lung disease, and a Phase 2 trial in Systemic sclerosis-associated interstitial lung disease, the analyst tells investors in a research note. Cantor is positive on Efzofitimod's prospects in pulmonary sarcoidosis and estimates that it can show a 30% relative reduction in daily steroid use in Phase 3 that should lead to blockbuster commercial opportunity in PS. The firm thinks the stock is pricing in just a 10% probability of success for the Phase 3 in PS vs. the firm's assumption of a 60% POS.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$35
2024-12-10
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$35
2024-12-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$35
2024-12-03
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$35
2024-12-03
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for aTyr Pharma Inc (ATYR.O) is -8.66, compared to its 5-year average forward P/E of -2.61. For a more detailed relative valuation and DCF analysis to assess aTyr Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.61
Current PE
-8.66
Overvalued PE
-1.10
Undervalued PE
-4.11
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.20
Current EV/EBITDA
-6.44
Overvalued EV/EBITDA
0.56
Undervalued EV/EBITDA
-2.95
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
477.32
Current PS
75.54
Overvalued PS
1482.24
Undervalued PS
-527.59
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
-5.19%
-15.77M
Operating Profit
FY2025Q1
YoY :
-3.91%
-14.88M
Net Income after Tax
FY2025Q1
YoY :
-26.09%
-0.17
EPS - Diluted
FY2025Q1
YoY :
-31.15%
-15.42M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.1K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
15.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 400% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
1,000K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
375.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.1K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
15.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATYR News & Events
Events Timeline
2025-07-22 (ET)
2025-07-22
08:05:00
aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study

2025-06-26 (ET)
2025-06-26
08:15:15
aTyr Pharma to be added to Russell 2000, Russell 3000 Indices

2025-06-04 (ET)
2025-06-04
08:06:01
aTyr Pharma announces interim analysis from Phase 2 EFZO-CONNECT

Sign Up For More Events
Sign Up For More Events
News
9.5
07-23BenzingaGE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
2.0
07-20NASDAQ.COMATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit…
4.5
06-26NASDAQ.COMaTyr Pharma to Be Added to Russell 2000® and Russell 3000® Indexes Effective June 27, 2025
Sign Up For More News
People Also Watch

CPZ
Calamos Long/Short Equity & Dynamic Income Trust
16.200
USD
-0.61%

OBT
Orange County Bancorp Inc
26.400
USD
-2.19%

NODK
NI Holdings Inc
13.210
USD
-0.30%

FSTR
L B Foster Co
24.630
USD
+2.37%

GTN
Gray Media Inc
4.970
USD
-3.31%

LNZA
Lanzatech Global Inc
0.582
USD
+2.11%

TRUE
TrueCar Inc
1.960
USD
+0.51%

SFST
Southern First Bancshares Inc
44.370
USD
-1.42%

VPG
Vishay Precision Group Inc
28.050
USD
+2.82%

EXFY
Expensify Inc
2.220
USD
0.00%
FAQ

What is aTyr Pharma Inc (ATYR) stock price today?
The current price of ATYR is 5.83 USD — it has increased 4.95 % in the last trading day.

What is aTyr Pharma Inc (ATYR)'s business?

What is the price predicton of ATYR Stock?

What is aTyr Pharma Inc (ATYR)'s revenue for the last quarter?

What is aTyr Pharma Inc (ATYR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for aTyr Pharma Inc (ATYR)'s fundamentals?

How many employees does aTyr Pharma Inc (ATYR). have?
